Who owns the IP
The organizations most actively patenting around this compound, ranked by referenced patent volume.
| # | Assignee | Patents |
|---|---|---|
| 1 | Ascendis Pharma AS | 23 |
| 2 | Bayer AG | 22 |
| 3 | H Lundbeck AS | 20 |
| 4 | Alcon Inc | 15 |
| 5 | Otsuka Holdings Co Ltd | 9 |
| 6 | Ono Pharmaceutical Co Ltd | 4 |
| 7 | Novartis AG | 2 |
| 8 | GSK PLC | 1 |
Explore the full landscape
This preview shows the leading assignees. Cypris reveals the full ownership landscape - every filing entity, filing trends, and portfolio momentum.
Visit CyprisWhere innovation is concentrated
Patent classifications ranked by volume reveal the technical domains with the most active filing.
| # | Code | Area | Patents |
|---|---|---|---|
| 1 | A61K | Medicinal preparations | 103 |
| 2 | A61P | Therapeutic activity (drug indications) | 102 |
| 3 | C07D | Heterocyclic compounds | 57 |
| 4 | Y02P | Climate change mitigation: production | 24 |
| 5 | Y10T | Cross-reference (technical subjects) | 23 |
| 6 | G01N | Investigating / analysing materials | 17 |
| 7 | C08J | Working-up of plastics | 7 |
| 8 | C07K | Peptides | 6 |
| 9 | A61M | Devices for introducing media into the body | 1 |
| 10 | C12Q | Measuring/testing involving enzymes | 1 |
AI mapped opportunity space
This preview shows where patent activity concentrates. Cypris maps the full classification landscape to surface technical whitespace and IP headroom.
See Cypris in actionRepresentative patents
The filings that best characterise the patent activity around this compound, most-referenced first.
| Title | Year | Assignee | Cited by |
|---|---|---|---|
| DIPEPTIDE-BASED PRODRUG LINKERS FOR ALIPHATIC AMINE-CONTAINING DRUGS | 2011 | Ascendis Pharma AS | 179 |
| BIODEGRADABLE POLYETHYLENE GLYCOL BASED WATER-INSOLUBLE HYDROGELS | 2011 | Ascendis Pharma AS | 176 |
| 1- [2- (2, 4-DIMETHYLPHENYLSULFANYL) -PHENYL] PIPERAZINE AS A COMPOUND WITH COMBINED SEROTONIN REUPTAKE, 5-HT3 AND 5-HT1A ACTIVITY FOR THE TREATMENT OF COGNITIVE IMPAIRMENT | 2007 | H Lundbeck AS | 161 |
| POLYMERIC HYPERBRANCHED CARRIER-LINKED PRODRUGS | 2013 | Ascendis Pharma AS | 89 |
| PROTEIN CARRIER-LINKED PRODRUGS | 2013 | Ascendis Pharma AS | 78 |
Who's driving the science
The most-published authors working with this compound, alongside their primary affiliations.
| # | Author | Affiliation | Papers |
|---|---|---|---|
| 1 | Francesc Artigas | Institut d'Investigacions Biomèdiques de Barcelona | 6 |
| 2 | Frank Mauler | Bayer (Germany) | 4 |
| 3 | Josef Krieglstein | Philipps University of Marburg | 4 |
| 4 | Christine Schaper | Philipps University of Marburg | 4 |
| 5 | Irina Semkova | Philipps University of Marburg | 3 |
| 6 | Pau Celada | Consorci Institut D'Investigacions Biomediques August Pi I Sunyer | 3 |
| 7 | Lorenzo Díaz-Mataix | Institut d'Investigacions Biomèdiques de Barcelona | 3 |
| 8 | Michael Böettcher | Bayer (Germany) | 3 |
| 9 | Georg Wensing | Bayer (Germany) | 3 |
| 10 | Barbara Ahlemeyer | Philipps University of Marburg | 2 |
Research leaders
This preview lists the top authors. Cypris surfaces the full researcher landscape, their affiliations, and how scientific influence is shifting.
See Cypris in actionThe literature that defines it
The most-cited papers anchoring the scientific record for this compound.
| Title | Year | Cited by | Topic |
|---|---|---|---|
| Postsynaptic 5-HT1A receptors control 5-HT release in the rat medial prefrontal cortex | 1999 | 119 | Neurotransmitter Receptor Influence on Behavior |
| The selective 5-HT1A receptor agonist repinotan HCl attenuates histopathology and spatial learning deficits following traumatic brain injury in rats | 2001 | 88 | Cardiac Arrest and Resuscitation |
| The G protein-coupled 5-HT1A receptor causes suppression of caspase-3 through MAPK and protein kinase Cα | 2003 | 82 | Protein Kinase Regulation and GTPase Signaling |
| 5-HT1A receptor agonist-mediated protection from MPTP toxicity in mouse and macaque models of Parkinson's disease | 2006 | 69 | Parkinson's Disease Mechanisms and Treatments |
| Characterization of the Aminomethylchroman Derivative BAY × 3702 as a Highly Potent 5-Hydroxytryptamine1A Receptor Agonist | 1998 | 55 | Neuropeptides and Animal Physiology |
Frequently asked questions
Common questions about this compound's patent and research landscape, answered from the underlying data.
What is the molecular composition of Repinotan hydrochloride?
Which organizations hold the most patents for Repinotan hydrochloride?
What is the current patent activity trend for Repinotan hydrochloride?
What are the primary research topics associated with Repinotan hydrochloride?
Who are the leading authors publishing on Repinotan hydrochloride?